132 related articles for article (PubMed ID: 11398844)
1. Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides.
Tsuda N; Murayama K; Ishida H; Matsunaga K; Komiya S; Itoh K; Yamada A
J Orthop Res; 2001 May; 19(3):346-51. PubMed ID: 11398844
[TBL] [Abstract][Full Text] [Related]
2. Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients.
Suefuji Y; Sasatomi T; Shichijo S; Nakagawa S; Deguchi H; Koga T; Kameyama T; Itoh K
Br J Cancer; 2001 Apr; 84(7):915-9. PubMed ID: 11286471
[TBL] [Abstract][Full Text] [Related]
3. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
4. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.
Tahara K; Takesako K; Sette A; Celis E; Kitano S; Akiyoshi T
Clin Cancer Res; 1999 Aug; 5(8):2236-41. PubMed ID: 10473111
[TBL] [Abstract][Full Text] [Related]
5. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
Cancer Res; 1999 Aug; 59(16):4056-63. PubMed ID: 10463607
[TBL] [Abstract][Full Text] [Related]
6. Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
Homma S; Harada M; Yano H; Ogasawara S; Shichijo S; Matsueda S; Komatsu N; Shomura H; Maeda Y; Sato Y; Todo S; Itoh K
Int J Oncol; 2006 Sep; 29(3):577-87. PubMed ID: 16865273
[TBL] [Abstract][Full Text] [Related]
7. Expression of tumor-rejection antigens in gynecologic cancers.
Tanaka S; Tsuda N; Kawano K; Sakamoto M; Nishida T; Hashimoto T; Shichijo S; Kamura T; Itoh K
Jpn J Cancer Res; 2000 Nov; 91(11):1177-84. PubMed ID: 11092984
[TBL] [Abstract][Full Text] [Related]
8. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
Azuma K; Sasada T; Takedatsu H; Shomura H; Koga M; Maeda Y; Yao A; Hirai T; Takabayashi A; Shichijo S; Itoh K
Clin Cancer Res; 2004 Oct; 10(19):6695-702. PubMed ID: 15475460
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma.
Tsukahara T; Kawaguchi S; Torigoe T; Kimura S; Murase M; Ichimiya S; Wada T; Kaya M; Nagoya S; Ishii T; Tatezaki S; Yamashita T; Sato N
Cancer Sci; 2008 Feb; 99(2):368-75. PubMed ID: 18271936
[TBL] [Abstract][Full Text] [Related]
10. Expression of the SART3 tumor rejection antigen in renal cell carcinoma.
Kawagoe N; Shintaku I; Yutani S; Etoh H; Matuoka K; Noda S; Itoh K
J Urol; 2000 Dec; 164(6):2090-5. PubMed ID: 11061933
[TBL] [Abstract][Full Text] [Related]
11. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
Komohara Y; Harada M; Ishihara Y; Suekane S; Noguchi M; Yamada A; Matsuoka K; Itoh K
Oncol Rep; 2007 Dec; 18(6):1463-8. PubMed ID: 17982631
[TBL] [Abstract][Full Text] [Related]
12. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
[TBL] [Abstract][Full Text] [Related]
13. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides.
Murayama K; Kobayashi T; Imaizumi T; Matsunaga K; Kuramoto T; Shigemori M; Shichijo S; Itoh K
J Immunother; 2000; 23(5):511-8. PubMed ID: 11001544
[TBL] [Abstract][Full Text] [Related]
14. Expression of SART3 tumor-rejection antigen in gastric cancers.
Niiya F; Nishizaka S; Matsunaga K; Koufuji K; Mori M; Katai H; Yamana H; Itoh K
Jpn J Cancer Res; 2000 Mar; 91(3):337-42. PubMed ID: 10760694
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
[TBL] [Abstract][Full Text] [Related]
16. Expression of the SART1 tumor-rejection antigen in human osteosarcomas.
Ishida H; Komiya S; Inoue Y; Yutani S; Inoue A; Itoh K
Int J Oncol; 2000 Jul; 17(1):29-32. PubMed ID: 10853014
[TBL] [Abstract][Full Text] [Related]
17. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
18. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.
Matsueda S; Yao A; Ishihara Y; Ogata R; Noguchi M; Itoh K; Harada M
Prostate; 2004 Aug; 60(3):205-13. PubMed ID: 15176050
[TBL] [Abstract][Full Text] [Related]
19. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
[TBL] [Abstract][Full Text] [Related]
20. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
